The relative contribution of antibody and CD8+ T cells to vaccine immunity against West Nile encephalitis virus

Vaccine

Volumn 26, Issue 16, 2008, Pages 2020-2033

  Shrestha, Bimmi ^a   Ng, Terry ^b   Chu, Hsien Jue ^b   Noll, Michelle ^a   Diamond, Michael S ^a  

^a WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b ZOETIS   (United States)

Author keywords

Antibody; CD8+ T cell; Flavivirus; Immunity; Pathogenesis; Vaccine

Indexed keywords

ADJUVANT; INACTIVATED VACCINE; METASTIM; NEUTRALIZING ANTIBODY; PLASMID DNA; UNCLASSIFIED DRUG; WEST NILE INNOVATOR; WEST NILE VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ANTIBODY TITER; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; DRUG EFFICACY; IMMUNIZATION; MORTALITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; RNA VIRUS INFECTION; SINGLE DRUG DOSE; SURVIVAL RATE; VIRUS LIKE AGENT; WEST NILE FLAVIVIRUS;

ANIMALS; ANTIBODIES, VIRAL; ANTIBODY SPECIFICITY; ANTIGENS, CD8; CD8-POSITIVE T-LYMPHOCYTES; IMMUNIZATION, SECONDARY; INJECTIONS, INTRAMUSCULAR; INJECTIONS, INTRAPERITONEAL; MICE; MICE, CONGENIC; MICE, INBRED C57BL; NEUTRALIZATION TESTS; PLASMIDS; VACCINES, DNA; VIRAL VACCINES; WEST NILE FEVER; WEST NILE VIRUS;

EID: 40849107822     PISSN: 0264410X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.vaccine.2008.02.009     Document Type: Article

References (56)

1. Diamond M.S. Development of effective therapies against West Nile virus infection. Expert Rev Anti Infect Ther 3 6 (2005) 931-944
2. Asnis D.S., Conetta R., Waldman G., and Teixeira A.A. The West Nile virus encephalitis outbreak in the United States (1999-2000): from Flushing, New York, to beyond its borders. Ann N Y Acad Sci 951 (2001) 161-171
3. Hubalek Z., and Halouzka J. West Nile fever-a reemerging mosquito-borne viral disease in Europe. Emerg Infect Dis 5 5 (1999) 643-650
4. Samuel M.A., and Diamond M.S. Pathogenesis of West Nile Virus infection: a balance between virulence, innate and adaptive immunity, and viral evasion. J Virol 80 19 (2006) 9349-9360
5. Diamond M.S., Shrestha B., Marri A., Mahan D., and Engle M. B cells and antibody play critical roles in the immediate defense of disseminated infection by West Nile encephalitis virus. J Virol 77 4 (2003) 2578-2586
6. Engle M.J., and Diamond M.S. Antibody prophylaxis and therapy against West Nile virus infection in wild-type and immunodeficient mice. J Virol 77 24 (2003) 12941-12949
7. Oliphant T., Engle M., Nybakken G.E., Doane C., Johnson S., Huang L., et al. Development of a humanized monoclonal antibody with therapeutic potential against West Nile virus. Nat Med 11 5 (2005) 522-530
8. Oliphant T., Nybakken G.E., Engle M., Xu Q., Nelson C.A., Sukupolvi-Petty S., et al. Antibody recognition and neutralization determinants on domains I and II of West Nile Virus envelope protein. J Virol 80 24 (2006) 12149-12159
9. Ben-Nathan D., Lustig S., Tam G., Robinzon S., Segal S., and Rager-Zisman B. Prophylactic and therapeutic efficacy of human intravenous immunoglobulin in treating West Nile virus infection in mice. J Infect Dis 188 1 (2003) 5-12
10. Throsby M., Geuijen C., Goudsmit J., Bakker A.Q., Korimbocus J., Kramer R.A., et al. Isolation and characterization of human monoclonal antibodies from individuals infected with West Nile Virus. J Virol 80 14 (2006) 6982-6992
11. Gould L.H., Sui J., Foellmer H., Oliphant T., Wang T., Ledizet M., et al. Protective and therapeutic capacity of human single-chain Fv-Fc fusion proteins against West Nile virus. J Virol 79 23 (2005) 14606-14613
12. Chang G.J., Kuno G., Purdy D.E., and Davis B.S. Recent advancement in flavivirus vaccine development. Expert Rev Vaccines 3 2 (2004) 199-220
13. Malkinson M., Banet C., Khinich Y., Samina I., Pokamunski S., and Weisman Y. Use of live and inactivated vaccines in the control of West Nile fever in domestic geese. Ann N Y Acad Sci 951 (2001) 255-261
14. Samina I., Khinich Y., Simanov M., and Malkinson M. An inactivated West Nile virus vaccine for domestic geese-efficacy study and a summary of 4 years of field application. Vaccine 23 41 (2005) 4955-4958
15. Tesh R.B., Siirin M., Guzman H., Travassos da Rosa A.P., Wu X., Duan T., et al. Persistent West Nile virus infection in the golden hamster: studies on its mechanism and possible implications for other flavivirus infections. J Infect Dis 192 2 (2005) 287-295
16. Gardner I.A., Wong S.J., Ferraro G.L., Balasuriya U.B., Hullinger P.J., Wilson W.D., et al. Incidence and effects of West Nile virus infection in vaccinated and unvaccinated horses in California. Vet Res 38 1 (2007) 109-116
17. Ng T., Hathaway D., Jennings N., Champ D., Chiang Y.W., and Chu H.J. Equine vaccine for West Nile virus. Dev Biol (Basel) 114 (2003) 221-227
18. Davis B.S., Chang G.J., Cropp B., Roehrig J.T., Martin D.A., Mitchell C.J., et al. West Nile virus recombinant DNA vaccine protects mouse and horse from virus challenge and expresses in vitro a noninfectious recombinant antigen that can be used in enzyme-linked immunosorbent assays. J Virol 75 9 (2001) 4040-4047
19. Schuler L.A., Khaitsa M.L., Dyer N.W., and Stoltenow C.L. Evaluation of an outbreak of West Nile virus infection in horses: 569 cases (2002). J Am Vet Med Assoc 225 7 (2004) 1084-1089
20. Siger L., Bowen R.A., Karaca K., Murray M.J., Gordy P.W., Loosmore S.M., et al. Assessment of the efficacy of a single dose of a recombinant vaccine against West Nile virus in response to natural challenge with West Nile virus-infected mosquitoes in horses. Am J Vet Res 65 11 (2004) 1459-1462
21. Yang J.S., Kim J.J., Hwang D., Choo A.Y., Dang K., Maguire H., et al. Induction of potent Th1-type immune responses from a novel DNA vaccine for West Nile virus New York isolate (WNV-NY1999). J Infect Dis 184 7 (2001) 809-816
22. Chang G.J., Davis B.S., Hunt A.R., Holmes D.A., and Kuno G. Flavivirus DNA vaccines: current status and potential. Ann N Y Acad Sci 951 (2001) 272-285
23. Turell M.J., Bunning M., Ludwig G.V., Ortman B., Chang J., Speaker T., et al. DNA vaccine for West Nile virus infection in fish crows (Corvus ossifragus). Emerg Infect Dis 9 9 (2003) 1077-1081
24. Wang T., Anderson J.F., Magnarelli L.A., Wong S.J., Koski R.A., and Fikrig E. Immunization of mice against West Nile virus with recombinant envelope protein. J Immunol 167 9 (2001) 5273-5277
25. Chu J.H., Chiang C.C., and Ng M.L. Immunization of flavivirus West Nile recombinant envelope domain III protein induced specific immune response and protection against West Nile virus infection. J Immunol 178 5 (2007) 2699-2705
26. Martina B.E., Koraka P., van den Doel P., van Amerongen G., Rimmelzwaan G.F., and Osterhaus A.D. Immunization with West Nile virus envelope domain III protects mice against lethal infection with homologous and heterologous virus. Vaccine 26 2 (2008) 153-157
27. Lustig S., Olshevsky U., Ben-Nathan D., Lachmi B.E., Malkinson M., Kobiler D., et al. A live attenuated West Nile virus strain as a potential veterinary vaccine. Viral Immunol 13 4 (2000) 401-410
28. Yamshchikov G., Borisevich V., Seregin A., Chaporgina E., Mishina M., Mishin V., et al. An attenuated West Nile prototype virus is highly immunogenic and protects against the deadly NY99 strain: a candidate for live WN vaccine development. Virology 330 1 (2004) 304-312
29. Hall R.A., Nisbet D.J., Pham K.B., Pyke A.T., Smith G.A., and Khromykh A.A. DNA vaccine coding for the full-length infectious Kunjin virus RNA protects mice against the New York strain of West Nile virus. Proc Natl Acad Sci USA 100 18 (2003) 10460-10464
30. Arroyo J., Miller C., Catalan J., Myers G.A., Ratterree M.S., Trent D.W., et al. ChimeriVax-West Nile virus live-attenuated vaccine: preclinical evaluation of safety, immunogenicity, and efficacy. J Virol 78 22 (2004) 12497-12507
31. Borisevich V., Seregin A., Nistler R., Mutabazi D., and Yamshchikov V. Biological properties of chimeric West Nile viruses. Virology 349 2 (2006) 371-381
32. Monath T.P., Liu J., Kanesa-Thasan N., Myers G.A., Nichols R., Deary A., et al. A live, attenuated recombinant West Nile virus vaccine. Proc Natl Acad Sci USA 103 17 (2006) 6694-6699
33. Ebel G.D., Dupuis II A.P., Ngo K., Nicholas D., Kauffman E., Jones S.A., et al. Partial genetic characterization of West Nile virus strains, New York State, 2000. Emerg Infect Dis 7 4 (2001) 650-653
34. Shrestha B., Wang T., Samuel M.A., Whitby K., Craft J., Fikrig E., et al. Gamma interferon plays a crucial early antiviral role in protection against West Nile virus infection. J Virol 80 11 (2006) 5338-5348
35. McClellan J.S., Tibbetts S.A., Gangappa S., Brett K.A., and Virgin H.W.t. Critical role of CD4 T cells in an antibody-independent mechanism of vaccination against gammaherpesvirus latency. J Virol 78 13 (2004) 6836-6845
36. Shrestha B., Samuel M.A., and Diamond M.S. CD8+ T cells require perforin to clear West Nile virus from infected neurons. J Virol 80 1 (2006) 119-129
37. Sitati E.M., and Diamond M.S. CD4+ T-cell responses are required for clearance of West Nile virus from the central nervous system. J Virol 80 24 (2006) 12060-12069
38. Purtha W.E., Myers N., Mitaksov V., Sitati E., Connolly J., Fremont D.H., et al. Antigen-specific cytotoxic T lymphocytes protect against lethal West Nile virus encephalitis. Eur J Immunol 37 7 (2007) 1845-1854
39. Brien J.D., Uhrlaub J.L., and Nikolich-Zugich J. Protective capacity and epitope specificity of CD8(+) T cells responding to lethal West Nile virus infection. Eur J Immunol 37 7 (2007) 1855-1863
40. Diamond M.S., Sitati E.M., Friend L.D., Higgs S., Shrestha B., and Engle M. A critical role for induced IgM in the protection against West Nile virus infection. J Exp Med 198 12 (2003) 1853-1862
41. Pincus S., Mason P.W., Konishi E., Fonseca B.A., Shope R.E., Rice C.M., et al. Recombinant vaccinia virus producing the prM and E proteins of yellow fever virus protects mice from lethal yellow fever encephalitis. Virology 187 1 (1992) 290-297
42. Samuel M.A., and Diamond M.S. Alpha/beta interferon protects against lethal West Nile virus infection by restricting cellular tropism and enhancing neuronal survival. J Virol 79 21 (2005) 13350-13361
43. Shrestha B., and Diamond M.S. Role of CD8+ T cells in control of West Nile virus infection. J Virol 78 15 (2004) 8312-8321
44. Wang Y., Lobigs M., Lee E., and Mullbacher A. CD8+ T cells mediate recovery and immunopathology in West Nile virus encephalitis. J Virol 77 24 (2003) 13323-13334
45. Steinman R.M., and Pope M. Exploiting dendritic cells to improve vaccine efficacy. J Clin Invest 109 12 (2002) 1519-1526
46. Sigal L.J., Crotty S., Andino R., and Rock K.L. Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. Nature 398 6722 (1999) 77-80
47. Chang G.J., Hunt A.R., and Davis B. A single intramuscular injection of recombinant plasmid DNA induces protective immunity and prevents Japanese encephalitis in mice. J Virol 74 9 (2000) 4244-4252
48. Pan C.H., Chen H.W., Huang H.W., and Tao M.H. Protective mechanisms induced by a Japanese encephalitis virus DNA vaccine: requirement for antibody but not CD8(+) cytotoxic T-cell responses. J Virol 75 23 (2001) 11457-11463
49. Simmons M., Porter K.R., Hayes C.G., Vaughn D.W., and Putnak R. Characterization of antibody responses to combinations of a dengue virus type 2 DNA vaccine and two dengue virus type 2 protein vaccines in rhesus macaques. J Virol 80 19 (2006) 9577-9585
50. Phillpotts R.J., Venugopal K., and Brooks T. Immunisation with DNA polynucleotides protects mice against lethal challenge with St. Louis encephalitis virus. Arch Virol 141 3-4 (1996) 743-749
51. Colombage G., Hall R., Pavy M., and Lobigs M. DNA-based and alphavirus-vectored immunisation with prM and E proteins elicits long-lived and protective immunity against the flavivirus, Murray Valley encephalitis virus. Virology 250 1 (1998) 151-163
52. Schmaljohn C., Vanderzanden L., Bray M., Custer D., Meyer B., Li D., et al. Naked DNA vaccines expressing the prM and E genes of Russian spring summer encephalitis virus and Central European encephalitis virus protect mice from homologous and heterologous challenge. J Virol 71 12 (1997) 9563-9569
53. Putnak R., Barvir D.A., Burrous J.M., Dubois D.R., D'Andrea V.M., Hoke C.H., et al. Development of a purified, inactivated, dengue-2 virus vaccine prototype in Vero cells: immunogenicity and protection in mice and rhesus monkeys. J Infect Dis 174 6 (1996) 1176-1184
54. Wolf R.F., Papin J.F., Hines-Boykin R., Chavez-Suarez M., White G.L., Sakalian M., et al. Baboon model for West Nile virus infection and vaccine evaluation. Virology 355 1 (2006) 44-51
55. Morrey J.D., Siddharthan V., Olsen A.L., Roper G.Y., Wang H., Baldwin T.J., et al. Humanized monoclonal antibody against West Nile virus envelope protein administered after neuronal infection protects against lethal encephalitis in hamsters. J Infect Dis 194 9 (2006) 1300-1308
56. Monath T.P. Prospects for development of a vaccine against the West Nile virus. Ann N Y Acad Sci 951 (2001) 1-12